Closing the Quality Chasm in Cirrhosis
Kai Rou Tey, Prashanthinie Mohan, Xibei Liu, Archita P. Desai – 7 September 2018
Closing the Quality Chasm in Cirrhosis
Kai Rou Tey, Prashanthinie Mohan, Xibei Liu, Archita P. Desai – 7 September 2018
High‐Mobility Group Box‐1 and Liver Disease
Harriet Gaskell, Xiaodong Ge, Natalia Nieto – 7 September 2018 – High‐mobility group box‐1 (HMGB1) is a ubiquitous protein. While initially thought to be simply an architectural protein due to its DNA‐binding ability, evidence from the last decade suggests that HMGB1 is a key protein participating in the pathogenesis of acute liver injury and chronic liver disease.
PRO: Redistricting of United Network for Organ Sharing Regions to Improve Geographic Disparities in Liver Transplantation
Fernando H. Calmet, Maria Samuel, Paul Martin – 7 September 2018
Geographic Areas of Liver Distribution in the United States Should Not Be Redesigned According to the 2016 Eight‐District Organ Procurement and Transplantation Network Proposal
Jennifer Batisti, Emily A. Schonfeld, Clara Tow, Robert S. Brown – 7 September 2018
Viability Criteria for Functional Assessment of Donor Livers During Normothermic Machine Perfusion
Otto B. van Leeuwen, Vincent E. de Meijer, Robert J. Porte – 7 September 2018
Dipeptidyl Peptidase‐4 Is a Pro‐Recovery Mediator During Acute Hepatotoxic Damage and Mirrors Severe Shifts in Kupffer Cells
Nádia Duarte, Inês Coelho, Denys Holovanchuk, Joana Inês Almeida, Carlos Penha‐Gonçalves, Maria Paula Macedo – 7 September 2018 – Dipeptidyl peptidase‐4 (DPP‐4 or clusters of differentiation [CD]26) is a multifunctional molecule with established roles in metabolism. Pharmacologic inhibition of DPP‐4 is widely used to improve glycemic control through regulation of the incretin effect. Colaterally, CD26/DPP‐4 inhibition appears to be beneficial in many inflammatory conditions, namely in delaying progression of liver pathology.
Follicular T Helper Cell Signatures in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
Leonie Adam, Katharina Zoldan, Maike Hofmann, Michael Schultheiss, Dominik Bettinger, Christoph Neumann‐Haefelin, Robert Thimme, Tobias Boettler – 7 September 2018 – Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are the most common cholestatic liver diseases. While PBC is generally accepted to be an autoimmune disorder characterized by pathognomonic autoantibodies against mitochondrial antigens, the pathogenesis of PSC is less precisely defined; however, some degree of altered immunity toward autoantigens has been suggested.
The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes
Carrie R. Wong, Joseph K. Lim – 7 September 2018